INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. In the past two decades, the role of the IGF axis in the pathogenesis of various neoplasms, including HCC, has been a focus of research \[[@R1]\]. Some case--control studies have supported a positive association between the insulin-like growth factor-1 (IGFI) level and the risk of liver cancer \[[@R2]--[@R4]\]. Indeed, in clinical practice, IGFI is used to assess HCC reserve capacity \[[@R5], [@R6]\] and as a prognostic marker for HCC progression and survival \[[@R3]\]. However, further research is needed.

Insulin-like growth factor-1 (IGF1), which is synthesised by the liver, is an important regulator of cellular proliferation, differentiation and apoptosis \[[@R7]--[@R9]\]. These effects can be inhibited by IGFBP3, which binds to and prevents IGFI from binding to type 1 insulin-like growth factor receptor (IGFI-R) \[[@R10]\]. About 99% of circulating IGF1 is bound to IGF-binding proteins, with most bound to IGF-binding protein 3 (IGFBP3). Less than 1% of circulating IGF1 is in an unbound form \[[@R11]\]. The IGF system is involved in the pathogenesis of several malignancies, including breast, prostate, colorectal, and gastric cancer \[[@R7], [@R9]\]. The development of HCC is reportedly correlated significantly with low IGFI and IGFBP3 levels and a high IGFI/IGFBP3 molar ratio \[[@R12]--[@R14]\]. Additionally, low baseline serum IGF1 levels are reportedly associated with shorter time-to-progression (TTP) and poorer overall survival (OS) in patients with HCC, irrespective of the grade of hepatic dysfunction \[[@R15], [@R16]\]. However, these studies were hampered by their low quality and small sample sizes. We performed a systematic review and meta-analysis of 20 studies to investigate the associations of IGF1 components with HCC and to examine their ability to predict the survival and prognosis of HCC patients.

RESULTS {#s2}
=======

Literature search and selection {#s2_1}
-------------------------------

Initially, 1172 records were retrieved by searching the Cochrane Library, PubMed, and EMBASE databases. After removal of duplicates, 834 articles were screened. Of these articles, 732 were excluded by reading the titles and abstracts, and the remaining 102 articles underwent detailed evaluation of the full text. A further 82 studies were excluded as they did not meet the inclusion criteria. Finally, 20 studies were included in our systematic review and meta-analysis: 3 case--control and 17 cohort studies (Figure [1](#F1){ref-type="fig"}). Eleven studies investigated the roles of IGF-1, IGFBP3, and the IGF-I/IGFBP3 molar ratio in the development of HCC (Table [1A](#T1){ref-type="table"}), and nine studies assessed the ability of serum IGF1 level to predict the TTP and OS of HCC patients (Table [1B](#T1){ref-type="table"}).

![Flow chart of the studies selected for systematic review and meta-analysis](oncotarget-08-81098-g001){#F1}

###### Characteristics of studies included in the review

###### (A) Studies of serum IGF-1 and IGFBP-3 levels and IGF-I/IGFBP-3 molar ratio among healthy, cirrhosis and HCC groups

  Study, year                       Location, setting                      Study design                Study period   Age, y   IGF-1/IGFBP-3 assay             HCC diagnosis              HCC, *n*   Cirrhosis case, *n*   Healthy controls, *n*   Adjusted confounders
  --------------------------------- -------------------------------------- --------------------------- -------------- -------- ------------------------------- -------------------------- ---------- --------------------- ----------------------- ------------------------------------------------------------------------------------------------------------
  Stuver et al, 2000^[@R2]^         USA, Hospital-based                    Case control                1995--1998     39--88   Chemiluminescence assay         Biopsy, AFP, US            73         NV                    111                     Gender, age
  Mazziottiet et al, 2002^[@R14]^   Italy, Hospital-based                  Cohort study                1995--2000     43--81   immunoradiometric assay         US, biopsy                 20         84                    NV                      Gender, age
  Mattera et al, 2003^[@R12]^       Italy, Hospital-based                  Cohort study                NA             25--75   immunoradiometric assay         US, Biopsy                 63         40                    150                     Age, diet
  Cujic et al, 2010^[@R39]^         Serbia, Hospital-based                 Cohort study                2008           20--75   radioimmunoassay                US, CT                     8          24                    31                      N A
  Major et al, 2010^[@R25]^         USA, population-based                  Cohort study                1985--1988     50--69   ELISA                           AFP, US, CT, MRI, biopsy   50         NA                    400                     Age,
  Su et al, 2010^[@R22]^            Taiwan, Hospital-based                 Cohort study                2005--2006     20--83   radioimmunoassay                Biopsy, AFP, US            65         NA                    165                     Recruitment center, date of blood collection
  Rehem et a,l 2011^[@R40]^         Egypt, Hospital-based                  Cohort study                2011           24--69   Immunoradiometric assay         CT or/and AFP              20         60                    20                      NA
  Aleem et al, 2012^[@R41]^         Egypt, Hospital-based                  Cohort study                2010--2011     NA       ELISA                           US, AFP                    62         79                    100                     Age, height, BMI
  Adamek et al, 2013^[@R42]^        Poland, Hospital-based                 Cohort study                2010--2012     18--63   immunoenzymetric assay, ELISA   USAFP                      61         37                    15                      Age, gender
  Lukanova et al, 2014^[@R3]^       European countries, population-based   nested case-control study   2002--2006     35--75   ELISA                           AFP, US, CT, MRI, biopsy   125        NA                    247                     Recruitment center, gender, age, date of blood collection
  Adachi et al, 2016^[@R4]^         Japan, population-based                nested case-control study   1997--2000     40--79   immunoradiometric assay         AFP, US, CT, MRI, biopsy   91         NA                    263                     gender, age, and residential area, Hepatitis viral infection, body mass index, smoking, and alcohol intake

###### (B) Ability of serum IGF1 level to predict the progression and survival of HCC patients

  Study, year                       Location, setting         Study design   Follow-up Period, m   age(mean or median),y   IGF-1/IGFBP-3 assay       HCC diagnosis              Cases, *n*   Outcomes index
  --------------------------------- ------------------------- -------------- --------------------- ----------------------- ------------------------- -------------------------- ------------ ----------------
  Treiber et al 2006^[@R26]^        Germany, Hospital-based   Cohort study   6                     65.7                    ESILA                     US, CT, MRI                71           OS, TTP
  Kaseb et al, 2011^[@R27]^         USA, Hospital-based       Cohort study   96                    60                      ELISA                     biopsy, US                 288          OS
  Shao et al, 2012^[@R28]^          Taiwan, Hospital-based    Cohort study   40                    54                      ELISA                     biopsy, AFP                83           OS, PFS
  Cho et al, 2013^[@R13]^           Korea, Hospital-based     Cohort study   72                    57.1                    immunoradiometric assay   AFP, US, CT, MRI, biopsy   91           OS, TTR
  Cho et al, 2014^[@R29]^           Korea, Hospital-based     Cohort study   41.8                  56                      immunoradiometric assay   AFP, US, CT, MRI, biopsy   155          OS, TTP
  Kaseb et al, 2014^[@R6]^          USA, Hospital-based       Cohort study   16.5                  60                      ELISA                     AFP, US, CT, MRI, biopsy   155          OS
  Abdel-Wahab et al, 2015^[@R15]^   Egypt, Hospital-based     Cohort study   6.5                   63.2                    ELISA                     Biopsy, CT                 100          OS
  Elmashad et al, 2015^[@R16]^      Egypt, Hospital-based     Cohort study   8                     51                      ELISA                     CT or /and AFP             89           OS, TTP
  Liu, 2016^[@R36]^                 China, Hospital-based     Cohort study   47                    55                      ELISA                     AFP, US, CT, MRI, biopsy   128          OS, TTP

Characteristics of participants {#s2_2}
-------------------------------

The characteristics of the participants are presented in Table [1A and 1B](#T1){ref-type="table"}. The study involved 1,798 HCC patients, 324 cirrhosis patients, and 1,502 healthy controls. The studies were published from 2000 to 2016. Seventeen were hospital-based studies, and three were population-based studies. Six studies were performed in Europe, four in the United States, four in Africa, and six in Asia. Of the 20 studies, 3 were case--control studies, and 17 were cohort studies; all involved only adults. Serum IGF1 and IGFBP3 levels were tested by enzyme-linked immunosorbent assay (ELISA) in all of the studies. The diagnosis of HCC was established based on biopsy, elevated alpha-fetoprotein level (AFP), and imaging techniques---such as ultrasound (US), three-phase dynamic computed tomography (CT), and magnetic resonance imaging (MRI)---according to the guidelines of the American Association for the Study of Liver Diseases \[[@R17]\].

Serum IGF1 and IGFBP-3 levels in the healthy, cirrhosis, and HCC groups {#s2_3}
-----------------------------------------------------------------------

The geometric mean serum levels of IGF1 and IGFBP3 differed significantly among the healthy, cirrhosis, and HCC groups independently of the degree of impairment of liver function (Table [2](#T2){ref-type="table"}). The serum IGF-I and IGFBP3 levels of the healthy group were significantly higher than those of the cirrhosis group (*p* \< 0.01). HCC was associated with lower serum IGF1 and IGFBP3 levels compared to liver cirrhosis (*p* = 0.037). The effects of different detection methods (ELISA and radioimmunoassay), research designs (case--control, cohort, and cross-sectional study), settings (hospital- and population-based), and locations (Asia, North America, and Europe) on serum IGF1 levels were assessed. In HCC patients, there was no difference between cohort and cross-sectional studies (*p* = 0.056) or between data collected in hospital- and population-based settings (*p* = 0.367) (Table [3](#T3){ref-type="table"}). Additionally, we assessed the association between the IGFI/ IGFBP3 molar ratio and the risk of HCC, odds ratio (OR, 1.311; 95% confidence interval (CI), 0.761--2.260; I-square, 46.86; *p* = 0.130) not showing a significant increase of IGF-I/IGFBP3 ratio in HCC incidence (data not shown).

###### Serum IGF1 and IGFBP-3 levels of the healthy, cirrhosis, and HCC groups

                                   *n*    Mean ± SD          *p* value
  -------------------------------- ------ ------------------ -----------
  **Serum IFG-1 level (ng/ml)**                              
  Healthy population               1255   181.34 ± 107.89    \< 0.001
  Cirrhosis patients               324    117.77 ± 109.69    0.037
  HCC patients                     432    102.91 ± 85.89     
  **Serum IFGBP3 level (ng/ml)**                             
  Healthy population               665    2608.35 ± 787.27   \< 0.001
  Cirrhosis patients               156    1278.84 ± 777.30   0.026
  HCC patients                     175    1092.38 ± 736.06   

###### Factors associated with serum IGF1 levels in the healthy, cirrhosis, and HCC groups

                          Health control   Cirrhosis         HCC                                                                   
  ----------------------- ---------------- ----------------- ---------- ----- ----------------- ---------- ----- ----------------- ----------
  **Detection methods**                                                                                                            
  ELISA                   626              190.61 ± 104.78   0.002      116   190.69 ± 139.42   \< 0.001   165   118.71 ± 93.41    0.005
  Radioimmunoassay        629              172.10 ± 110.20              208   77.11 ± 57.73                176   90.68 ± 90.48     
  **Research designs**                                                                                                             
  Case-control study      374              129.14 ± 63.20    \< 0.001                                      53    65.87 ± 45.99     0.008
  cohort study            415              145.69 ± 50.26    \< 0.001   121   68.00 ± 33.50     \< 0.001   70    91.94 ± 57.63     0.056
  cross-section study     466              254.98 ± 131.05              203   147.44 ± 127.29              218   117.52 ± 106.54   
  **Location settings**                                                                                                            
  hospital-based          592              236.75 ± 124.85   \< 0.001   324   117.77 ± 109.69              291   102.36 ± 98.12    0.367
  population-based        663              131.86 ± 54.19                                                  50    115.2 ± 51.61     
  **Study locations**                                                                                                              
  Asia                    548              209.26 ± 143.03   \< 0.001   139   168.28 ± 139.32              147   144.19 ± 114.71   \< 0.001
  North America           511              152.47 ± 54.12    \< 0.001                                      103   89.82 ± 54.51     \< 0.001
  Europe                  196              178.53 ± 73.61               185   79.82 ± 56.46     \< 0.001   91    56.04 ± 51.40     

Association of IGF1 level with TTP and OS {#s2_4}
-----------------------------------------

Low IGF1 levels were predictive of a shorter TTP (OR, 2.74; 95% CI, 1.92--3.90) and poorer OS (OR, 2.20; 95% CI, 1.81--2.68) in HCC patients, irrespective of the grade of hepatic dysfunction. No significant heterogeneity was observed among the studies. This suggests serum IGF1 level to be an independent prognostic factor for the survival (Figure [2A](#F2){ref-type="fig"}) and progression (Figure [2B](#F2){ref-type="fig"}) of HCC patients. The subgroup analysis indicated that use of different detection methods (ELISA and radioimmunoassay), research designs (clinical and cohort studies), and locations (Asia, North, America and Europe) had no significant influence on the TTP and OS of HCC patients (Table [4A and 4B](#T4){ref-type="table"}).

![Association between serum IGF1 level and HCC\
(**A**) Overall survival (OS); (**B**) time-to-progression (TTP).](oncotarget-08-81098-g002){#F2}

###### Subgroup analysis of the association between serum IGF1 level and HCC

###### (A) Overall survival (OS)

  Factors                Studies, *n*   OS for HCC (95%CI)      *I*^2^   Model used
  ---------------------- -------------- ----------------------- -------- ---------------
  **Detection method**                                                   
  ELISA                  6              2.311 (1.858---2.874)   31.4%    Fixed effects
  Radioimmunoassay       2              2.279 (1.448---3.587)   55.6%    Fixed effects
  **Study design**                                                       
  Clinical trail         3              2.073 (1.615---2.660)   0%       Fixed effects
  Cohort                 5              2.745 (1.993---3.781)   31.8%    Fixed effects
  **Study location**                                                     
  Asia                   5              2.489 (1.922---3.223)   41.6%    Fixed effects
  North America          2              2.082 (1.546---2.802)   0%       Fixed effects
  Europe                 1              3.2 (2.4---10.5)                 

###### (B) Time-to-progression (TTP)

  Factors                Studies,*n*   TTP for HCC (95%CI)     *I*^2^   Model used
  ---------------------- ------------- ----------------------- -------- ----------------
  **Detection method**                                                  
  ELISA                  3             3.275 (2.305---4.653)   43.1%    Fixed effects
  Radioimmunoassay       2             2.109 (1.422---3.128)   0%       Fixed effects
  **Study design**                                                      
  Clinical trail         2             2.623 (1.721---3.997)   0%       Fixed effects
  Cohort                 3             2.873 (1.530---5.394)   71.4%    Random effects
  **Study location**                                                    
  Asia                   4             2.718 (2.062---3.583)   57.1%    Fixed effects
  Europe                 1             2.5 (1.6---8.4)                  

Serum IGF1 levels according to clinical characteristics {#s2_5}
-------------------------------------------------------

The associations between clinical factors and baseline IGF1 levels are shown in Table [5](#T5){ref-type="table"}. HCC patients with the hepatitis C virus (HCV) infection had significantly lower IGF1 levels than those with the hepatitis B virus (HBV) infection (*p* = 0.034). HCC patients of Child--Pugh class C (*p* = 0.002), Barcelona Clinic Liver Cancer Stage-B (BCLC-B) (*p* \< 0.01), or BCLC-C (*p* = 0.019) had significantly lower baseline IGF1 levels. However, baseline IGF1 levels did not differ significantly according to age, gender, serum AFP level, tumour nodularity, or vascular invasion (*p* \> 0.05).

###### Serum levels of IGF1 according to the clinical characteristics of HCC patients

  Factor and subset                *n*                                 Mean ± SD        p value
  -------------------------------- ----------------------------------- ---------------- ----------
  **Age (years)**                  ![](oncotarget-08-81098-i001.jpg)                    
  \< 60                            333                                 99.42 ± 58.50    0.584
  ≥ 60                             195                                 96.23 ± 73.59    
  **Gender**                                                                            
  Female                           140                                 90.24 ± 53.50    0.4
  Male                             323                                 85.76 ± 52.08    
  **Hepatitis infection status**                                                        
  None                             36                                  101.58 ± 84.73   0.962
  HBV                              337                                 102.18 ± 70.57   0.034
  HCV                              57                                  81.25 ± 56.69    
  **Child-Pugh class**                                                                  
  A                                336                                 109.12 ± 76.76   0.653
  B                                137                                 112.94 ± 98.14   0.002
  C                                79                                  158.75 ± 117.3   
  **Serum AFP level(ng/ml)**                                                            
  \< 200                           264                                 87.45 ± 54.46    0.353
  ≥ 200                            120                                 93.23 ± 60.58    
  **Tumor nodularity**                                                                  
  Monofocal disease                155                                 76.19 ± 54.02    0.98
  Multifocal                       113                                 76.34 ± 42.77    
  **BCLC stage**                                                                        
  0                                45                                  100.56 ± 64.74   0.376
  A                                163                                 109.73 ± 60.53   \< 0.001
  B                                136                                 72.34 ± 46.13    0.019
  C                                99                                  86.29 ± 43.05    
  **Vascular invasion**                                                                 
  No                               147                                 80.21 ± 57.86    0.166
  Yes                              70                                  90.62 ± 34.48    

Publication bias {#s2_6}
----------------

No evidence of publication bias was detected in nine studies of the ability of serum IGF1 level to predict the OS rate of HCC patients (Begg test, *p* = 0.083; Egger test, *p* = 0.103) (Figure [3](#F3){ref-type="fig"}).

![Publication bias in studies of the association between serum IGF1 level and overall survival of HCC patients](oncotarget-08-81098-g003){#F3}

DISCUSSION {#s3}
==========

High levels of circulating IGF-I and low levels of IGFBP-3 are reportedly associated with an increased risk of several common cancers, including those of the prostate, breast, colon, and lung \[[@R18]--[@R20]\]. However, no systematic review has evaluated the associations of IGF1 and IGFBP3 levels with HCC. We conducted a systematic review and meta-analysis of the association of serum IGFI and IGFBP3 levels with the risk of HCC. Low levels of IGF1 and IGFBP-3 were positively associated with the risk of HCC independently of the degree of impairment of liver function, consistent with previous reports \[[@R2], [@R21], [@R22]\]. Additionally, patients with cirrhosis had lower circulating IGF1 and IGFBP3 levels than healthy controls (*p* \< 0.001). This is likely because of reduced secretion of the liver-derived factors IGF1 and IGFBP3 in cirrhosis and HCC patients with chronic liver damage and functional insufficiency \[[@R23]\].

The free form of IGF1 induces cell proliferation and inhibits apoptosis in bone, cartilage, the central nervous system, and the kidneys. The IGF1 to IGFBP3 molar ratio represents the level of active IGF1 \[[@R24]\], and patients with an IGF1 concentration higher than their IGFBP3 level are at an increased risk of liver cancer \[[@R25]\]. However, no significant association between the IGFI/IGFBP3 molar ratio and the risk of HCC (OR, 1.311; 95% CI, 0.761--2.260) was detected.

In HCC patients, a low serum IGF1 level was predictive of a shorter TTP (OR, 2.74; 95% CI, 1.92--3.90) and poorer OS (OR, 2.20; 95% CI, 1.81--2.68), with no heterogeneity (I-square = 0), irrespective of the grade of hepatic dysfunction, which is consistent with previous reports \[[@R6], [@R13], [@R15], [@R26]--[@R29]\]. Nine of the studies used identical statistical methods: (1) receiver-operating characteristic (ROC) curves for censored survival data to identify the optimum cut-off value for predicting outcome; \[[@R30]\] and (2) Cox proportional hazard regression analysis to evaluate independent risk factors for disease progression and OS \[[@R31]\] after adjustment for age, gender, HBV/HCV infection, AFP level, Child--Pugh class, BCLC stage, tumour nodularity, and vascular invasion. Serum IGF1 level was the most significant predictor of HCC progression and survival. A prospective study reported that a low IGF-I concentration at least 5 years before cancer diagnosis was associated with an increased risk of liver cancer \[[@R25]\]. Further, larger-scale studies of the ability of ILGF-1 level to predict HCC are warranted.

Additionally, circulating IGF-1 level was correlated with virus infection, Child--Pugh class, and BCLC stage of HCC patients. Therefore, the circulating IGF-1 level was associated with HCC progression. The circulating IGF-1 level is reportedly significantly correlated with survival, the synthetic function of the liver, and tumour parameters \[[@R27], [@R32]\]. Moreover, integrating plasma insulin-like growth factor-1 level into the Child--Turcotte--Pugh score (IGF-CTP score) resulted in improved risk stratification of HCC patients \[[@R6], [@R15]\]. The IGF-CTP score should thus be validated in further studies.

We analysed all available prospective studies that adjusted for potential risk factors, such as liver function and the clinical characteristics of HCC patients. However, this study had several limitations. First, the meta-analysis was vulnerable to the bias in the original studies, and the IGF1 and IGFBP3 assays and study design were not standardised, which led to different IGF1 and IGFBP3 levels among the studies. Future prospective studies should use a uniform study design and identical assays. Second, previous studies showed that energy and protein intake were associated with IGF1 and IGFBP3 concentrations^[@R33],[@R34]^, but we did not adjust for dietary parameters. Third, most of the included studies involved hospitalised patients, who may not be representative of the general population, likely leading to overestimation of the risk of HCC. Finally, the number of eligible studies was small, which may have influenced the accuracy of the results.

In conclusion, circulating IGF1 and IGFBP3 levels were positively associated with the incidence of HCC, and the IGF1 level emerged as an independent prognostic factor for the progression and survival of HCC patients. Therefore, further large-scale, well-designed studies that consider a larger number of confounding factors are warranted.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

Case--control and cohort studies were identified by searching PubMed, EMBASE, and the Cochrane Library using the following keywords: Insulin-like growth factor I, insulin-like growth factor binding protein 3, and hepatocellular carcinomas. Only English-language publications were included in the study. The databases were searched for articles published up to October 2016.

Selection of studies and data extraction {#s4_2}
----------------------------------------

we included observational studies that met all of the following inclusion criteria: (1) case--control or cohort design; (2) use of adult subjects; (3) inclusion of a healthy control group and HCC patients with cirrhosis; (4) measurement of serum levels of IGF1 and/or IGFBP3 and calculation of means ± SDs; (5) calculation of odds ratio (OR) or relative risk (RR) of IGF1 serum level for HCC progression and survival; and (6) written in the English language.

Data extraction and quality assessment {#s4_3}
--------------------------------------

Data extraction was conducted independently by J.W. and Y.-C.L., and discrepancies were resolved by D.M., H.-Y.J., L.-H.G., and W.-J.Z. before the final analysis. The following data were collected from each study: author, year of publication, study country, study setting, total number of subjects in each group, serological detection method for IGF1 and IGFBP3, basis for HCC diagnosis, and statistical adjustments made. The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) \[[@R35]\], which was developed to assess the quality of nonrandomised studies in meta-analyses. On this scale, observational studies are scored in three categories: selection (four questions) and comparability (two questions) of the study group, and ascertainment of the outcome of interest (three questions). All questions have a score of one, with the exception of those addressing the comparability of study groups, for which separate points are awarded for controlling for age and/or sex (maximum, two points). Studies with more than five points were included in the meta-analysis; one study \[[@R36]\] did not meet this criterion and was excluded from the analysis of the survival of HCC patients ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

Outcomes {#s4_4}
--------

The primary analysis assessed the association of serum IGF1 and IGFBP3 levels with the incidence of HCC and the ability of a low IGF1 serum level to predict HCC progression and survival. The serum IGF1 levels of the HCC patients were analysed according to their clinical characteristics, such as age, gender, AFP level, Child--Pugh class, BCLC stage, tumour nodularity, and vascular invasion.

Statistical analysis {#s4_5}
--------------------

statistical analysis was conducted using STATA 12.0 software (StataCorp LP, College Station, TX, USA). The Cochran Q chi-square test and the I^2^ statistic were used to assess heterogeneity among the studies \[[@R37]\]. An I^2^ value of \> 50% or a *p*-value of \< 0.05 for the Q-statistic was taken to indicate significant heterogeneity \[[@R38]\]. We used a fixed-effects model to estimate pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for HCC progression and survival. Additionally, the serum IGF1 and IGFBP levels of the healthy, cirrhosis, and HCC groups were subjected to one-way analysis of variance (ANOVA). Serum IGF1 levels were analysed according to the clinical characteristics of the HCC patients. Publication bias was analysed using a Begg funnel plot and the Egger test \[[@R43]\].

SUPPLEMENTARY FIGURE {#s5}
====================
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